Epidermal Growth Factor Receptor (EGFR/ERBB1/HER1) is one of four receptor tyrosine kinases (the others being ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4) belonging to the EGFR/ERBB family. Upon binding of one of its ligands (including EGF and TGFα) in a normal setting, EGFR forms homodimers or heterodimerizes with other family members and initiates signaling through major signaling pathways to mediate cell survival, proliferation, differentiation, and other essential functions (1). Dysregulation or mutation of EGFR is known to drive various human neoplasms, including breast, lung, and brain malignancies, in an essentially ligand-independent manner. Specific mutations in EGFR are recognized as tumor markers and play a crucial role in therapeutic decision-making (2, 3).
GeneTex has developed new recombinant rabbit monoclonal antibodies that detect particular mutations in EGFR. These reagents are the latest additions to an already broad catalog of products for EGFR research. Please see the product images below and go to www.genetex.com to learn more.
- Curr Top Med Chem. 2020;20(10):815-834.
- Sci Rep. 2015 Sep 4;5:13574.
- Oncogene. 2020 Mar;39(13):2643-2657.